Opinion
Debate: Is lasting remission of type 2 diabetes feasible in the real-world setting?
- Author:
- Kevin Fernando, MBChB, MSc
Publish date: October 18, 2023
Dr. Taylor suggested that we not label these individuals who have lost significant weight as having prediabetes. Instead “postdiabetes” should be...
Opinion
Beyond A1c: Implementing the new ESC 2023 guidelines
- Author:
- Kevin Fernando, MBChB, MSc
Publish date: September 21, 2023
Controversially, the updated ESC guidance suggests the use of metformin only in patients with type 2 diabetes and atherosclerotic cardiovascular...
Opinion
Oral GLP-1 agonists could be game changers for obesity
- Author:
- Kevin Fernando, MBChB, MSc
Publish date: July 6, 2023
I hope that future developments bring the class to an even wider demographic and perhaps reduce some of the global inequities in managing type 2...
Opinion
Tirzepatide: Therapeutic titan or costly cure?
- Author:
- Kevin Fernando, MBChB, MSc
Publish date: June 29, 2023
Positioning tirzepatide as the first injectable of choice after oral treatment escalation with metformin and an SGLT2 inhibitor may remain an...